Alkermes (ALKS) announced that the FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1, based on phase 1 and phase 2 clinical data, including results from Vibrance-1, a phase 2 study evaluating alixorexton in patients with NT1.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Centessa price target raised to $42 from $33 at B. Riley
- Jefferies expects Avadel-Alkermes deal to close
- Avadel Pharmaceuticals price target raised to $22.50 from $20 at Wells Fargo
- Cautious Optimism: Alkermes’ Strategic Moves and Market Potential Amidst Investor Concerns
- Alkermes Increases Offer for Avadel Acquisition